The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
- PMID: 17928528
- DOI: 10.1182/blood-2007-05-089037
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells
Abstract
Sustained engagement of the B-cell receptor (BCR) increases apoptosis resistance in chronic lymphocytic leukemia (CLL) B cells, whereas transient stimulation usually has an opposite effect. The antiapoptotic BCR signal has been associated with prolonged activation of the PI3K/Akt and MEK/ERK pathways, which are key regulators of survival and proliferation in various cell types. To further define the relative contribution of the Akt and ERK kinases in regulating CLL B-cell survival, we introduced constitutively active mutants of Akt and MEK in primary CLL B cells and evaluated changes in the expression of relevant pro- and antiapoptotic proteins. Sustained activation of Akt resulted in increased leukemic cell viability and increased expression of the antiapoptotic proteins Mcl-1, Bcl-xL, and X-linked inhibitor of apoptosis protein (XIAP), thus largely recapitulating the effects of sustained BCR stimulation. Constitutively active MEK2 also up-regulated XIAP, but did not show a significant impact on leukemic cell survival. Down-regulation of Mcl-1 by siRNA treatment induced rapid and potent apoptosis in CLL B cells and blocked the antiapoptotic effect of sustained BCR stimulation, whereas down-regulation of Bcl-xL and XIAP did not affect leukemic cell viability. These data demonstrate that Akt and Mcl-1 are major components of a survival pathway that can be activated in CLL B cells by antigen stimulation.
Similar articles
-
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.Blood. 2005 Jun 15;105(12):4820-7. doi: 10.1182/blood-2004-07-2669. Epub 2005 Feb 22. Blood. 2005. PMID: 15728130
-
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.Leukemia. 2009 Apr;23(4):686-97. doi: 10.1038/leu.2008.346. Epub 2008 Dec 18. Leukemia. 2009. PMID: 19092849
-
The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.Oncogene. 2009 Sep 17;28(37):3261-73. doi: 10.1038/onc.2009.179. Epub 2009 Jul 6. Oncogene. 2009. PMID: 19581935
-
Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.Autoimmun Rev. 2007 Dec;7(2):102-8. doi: 10.1016/j.autrev.2007.02.021. Epub 2007 Mar 28. Autoimmun Rev. 2007. PMID: 18035318 Review.
-
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Biochim Biophys Acta. 2016 Mar;1863(3):401-413. doi: 10.1016/j.bbamcr.2015.07.009. Epub 2015 Jul 17. Biochim Biophys Acta. 2016. PMID: 26193078 Free PMC article. Review.
Cited by
-
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.Curr Hematol Malig Rep. 2012 Mar;7(1):26-33. doi: 10.1007/s11899-011-0104-z. Curr Hematol Malig Rep. 2012. PMID: 22105489 Review.
-
Broad targeting of resistance to apoptosis in cancer.Semin Cancer Biol. 2015 Dec;35 Suppl(0):S78-S103. doi: 10.1016/j.semcancer.2015.03.001. Epub 2015 Apr 28. Semin Cancer Biol. 2015. PMID: 25936818 Free PMC article. Review.
-
Targeting the B cell receptor pathway in chronic lymphocytic leukemia.Leuk Lymphoma. 2012 Dec;53(12):2362-70. doi: 10.3109/10428194.2012.695781. Leuk Lymphoma. 2012. PMID: 22616724 Free PMC article. Review.
-
T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.Blood. 2012 Sep 20;120(12):2438-49. doi: 10.1182/blood-2012-02-409110. Epub 2012 Aug 8. Blood. 2012. PMID: 22875913 Free PMC article.
-
Vitamin C Supplementation in the Treatment of Autoimmune and Onco-Hematological Diseases: From Prophylaxis to Adjuvant Therapy.Int J Mol Sci. 2024 Jul 2;25(13):7284. doi: 10.3390/ijms25137284. Int J Mol Sci. 2024. PMID: 39000393 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous